

Cephameycins, a New Family of β -Lactam Antibiotics.

III. In Vitro Studies¹

A. KATHRINE MILLER, EVMARIE CELOZZI, BARBARA A. PELAK, EDWARD O. STAPLEY,
AND DAVID HENDLIN

Merck Institute for Therapeutic Research, Rahway, New Jersey 07065

Received for publication 23 May 1972

Cephameycins A, B, and C are naturally produced cephalosporin-type antibiotics. Although A and B were found to be more active than C against gram-positive organisms, they were not so active against such strains as are cephalosporin C or the semisynthetic antibiotics cephaloridine and cephalothin. Against gram-negative organisms, cephameycin C was more active than A or B and, in general, was as active as the cephalosporins. In addition, cephameycin C was active in vitro against clinically isolated strains resistant to the cephalosporins, such as *Proteus*, *Providencia*, and *Escherichia coli*. The in vitro antibacterial activity of cephameycin C, cephalothin, and cephaloridine is primarily bactericidal. A 10,000-fold increase in inoculum of a strain of *Proteus mirabilis* resulted in 200-fold or greater increases in minimal inhibitory and minimal bactericidal end points of cephalothin and cephaloridine, but only 10- and 16-fold increases, respectively, for cephameycin C. After 15 passages through antibiotic-containing broths, during which time a culture of *E. coli* showed an increase in minimal inhibitory concentrations of streptomycin of >1,000-fold, end points for cephameycin C increased 4-fold, for cephalothin, 1.5- to 6-fold, and for cephaloridine, 128-fold.

Cephameycins A, B, and C are naturally produced cephalosporin-type agents whose isolation and biological characterization have been described by Stapley et al. (2). All three cephameycins have been shown to be resistant to cephalosporinase by Daoust et al. (*submitted for publication*). Studies of their chemical structure will be reported by Albers-Schonberg et al. (*manuscript in preparation*).

This paper describes in vitro tests that were used to examine some of the characteristics of the antibacterial activities of these agents. In vivo studies are described by Miller et al. (1).

MATERIALS AND METHODS

Cephameycin preparations of approximately 70% purity were studied. Commercial samples of penicillin (The Upjohn Co.), streptomycin (Merck & Co., Inc.), cephalothin (Keflin, Eli Lilly & Co.), and cephaloridine (Loridine, Eli Lilly & Co.), and a laboratory sample of cephalosporin C were used as control materials. The bacterial cultures used are maintained in the Merck Sharp & Dohme stock culture collection and their designated numbers have no significance outside this company.

¹ Presented in part at the 11th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlantic City, N.J., 19-22 October 1971.

Agar MIC. The compounds were incorporated in twofold dilutions either in nutrient agar (BBL) plus sterile horse serum (Bioquest) to a final concentration of 10% or in brain-heart infusion agar (Difco) plus 10% horse serum. The test organisms were grown overnight in nutrient broth (Difco) or brain-heart infusion (BBL), which for some organisms was supplemented with horse serum to 10%. The plates were seeded with approximately 10⁴ or 10⁶ organisms by means of a multiple inoculator (3). After 24 hr of incubation at 37 C the minimal inhibitory concentration (MIC) was read as the smallest concentration permitting no growth. In addition to the cephameycins, cephalothin, and cephaloridine, cephalosporin C was included in this test.

Speed of action of cephameycin C and the effect of whole blood on such activity. Test organisms were grown in brain-heart infusion broth for 2.5 hr (*Escherichia coli* 2017 and *Salmonella schottmuelleri* 3010) or 6 hr (*Proteus vulgaris* 1810) and were then diluted with brain-heart infusion broth or freshly drawn defibrinated rabbit blood to contain about 10⁶ cells/ml. A 9-ml amount of such seeded fluid was added to 1 ml of antibiotic solution or water. The bacterial population in such mixtures was determined by plate counts made at various time intervals during the incubation at 37 C. Each test was run twice, and the results were averaged.

Activity of cephameycin C against cephalosporin-resistant cultures. MIC values in broth were de-

terminated by use of 0.5-ml doubling drug dilutions seeded with 2.0 ml of brain heart infusion (BBL) containing approximately 10^4 organisms. Tubes were incubated at 37 C, and growth was recorded after 24 hr and again after 48 hr. All negative tubes were subcultured (0.2 ml into 9 ml of brain-heart infusion), and growth in such tubes was recorded after 72 hr at 37 C to determine the minimal bactericidal concentration (MBC). Included in this study were cephamycin C, cephalothin, cephaloridine, and streptomycin. The clinically isolated test organisms included five strains of *Proteus* and one of *E. coli*, chosen because they were resistant to cephalosporins.

Inoculum effect. The broth MIC test described above was set up so that replicate drug dilution series could be seeded with broths containing 10^8 , 10^6 , or 10^7 cells/ml. A clinically isolated strain of *P. mirabilis* was used against cephamycin C, cephalothin, and cephaloridine.

Serial transfer of *E. coli* through antibiotic-containing broth. The standard MIC test with seeded broth containing 10^7 cells/ml was used to determine the susceptibility of *E. coli* 2017 to cephamycin C, cephalothin, cephaloridine, and streptomycin. After the initial exposure, seeds of 10^6 to 10^7 cells/ml were prepared from that tube in the series which contained the highest concentration of antibiotic permitting maximal or almost maximal growth. MIC values were recorded at both 24 and 48 hr. Transfers into new drug series were made at 24 hr; subcultures for MBC values were made after the 48-hr reading. At the conclusion of the test, each exposed strain was tested against all four antibiotics in the standard MIC test, and the end points were compared with those of the parent strain recorded at the beginning of the test.

RESULTS

Agar dilution MIC. Table 1 lists the MIC values of cephamycins A, B, and C, cephalothin, cephaloridine, and cephalosporin C for 43 organisms representing 20 species of 15 genera of bacteria. It can be seen that, although cephamycins A and B were perhaps more active in vitro against gram-positive organisms than was cephamycin C, none of these was so active as cephalothin, cephaloridine, or cephalosporin C. Against the gram-negative organisms, none of the cephamycins or cephalosporins was active at these concentrations against the test strains of *Pseudomonas*, *Serratia*, and some *Aerobacter*. Against other gram-negative organisms, cephamycin C in general was not only more active than cephamycin A or B, but it was essentially as active as cephalothin. It is of interest that against many of these organisms cephamycin C was more active than the "natural" product cephalosporin C. Moreover, cephamycin C also was active against *P. morgani* strains that are resistant to the cephalosporins. Because cephamycin B activity

was relatively low, this compound was not included in the remaining in vitro tests.

Speed of action and effect of blood. The antibacterial activity of cephamycin C was as effective in whole blood as it was in brain heart infusion broth. Figures 1 and 2 show that 100 μ g of cephamycin C/ml of broth resulted in a decrease of 3 logs (99.9%) in the countable *E. coli* 2017 or *S. schottmuelleri* 3010 cells in less than 2 hr. A similar decrease was seen when the antibiotic and cells were suspended in rabbit blood. Figure 3 shows that against *P. vulgaris* 1810 25 μ g of antibiotic/ml of broth produced a 3 log decrease in count in 2 hr; the antibiotic action in blood was a bit slower. Higher concentrations of cephamycin C were not tested.

Organisms isolated from plates used for counting the antibiotic-containing cultures, as well as from control cultures, were tested by the agar-disc method for their in vitro susceptibility to cephamycin C. Zones of inhibition for the antibiotic-exposed cultures indicated no loss of susceptibility to the antibiotic.

Activity of cephamycin C against cephalosporin-resistant cultures. The MIC and MBC end points of a clinically isolated cephalosporin-resistant




FIG. 1. Effect of cephamycin C on a growing culture of *Escherichia coli* 2017.




FIG. 2. Effect of cephamicin C on a growing culture of *Salmonella schottmuelleri* 3010.




FIG. 3. Effect of cephamicin C on a growing culture of *Proteus vulgaris* 1810.

strain of *E. coli* and five such strains of *Proteus* are shown in Table 2. Included for comparison are end points of a clinically isolated cephalosporin-susceptible *Proteus* strain. Streptomycin was included in this test as a noncephalosporin type of bactericidal antibiotic.

The data show that these resistant *P. mirabilis* and *Proteus* sp. were less susceptible to cephaloridine than to cephalothin. Four of the five resistant *Proteus* cultures were susceptible to both cephamicin C and streptomycin. The fifth culture, *P.morganii* 3376, was resistant to streptomycin and was inhibited but not killed by high concentrations of cephamicin C. With this latter exception, a comparison of the MBC and MIC values for all of the *Proteus* and the *E. coli* cultures agree with the interpretation that all four antibiotics are bactericidal in action.

Inoculum effect. Increasing the inoculum of the clinically isolated *P. mirabilis* 3347 10,000-fold (from 10^3 to 10^7 cells/ml of broth) resulted in increases in the MIC or MBC of all of the antibiotics (Table 3). The cephamicin C increases were only 10- and 16-fold, whereas the MIC and MBC increased 200-fold or more for the cephalosporins.

Serial transfer of *E. coli* through antibiotic-containing broth. Table 4 lists the data obtained during 15 transfers of *E. coli* 2017 through broth containing cephamicin C, cephalothin, cephaloridine, or streptomycin. It can be seen that the MIC and MBC for streptomycin did increase, as expected, >1,000-fold. During this time, the MIC values for cephamicin C increased 4-fold, for cephalothin, 1.5- to 6-fold, and for cephaloridine, 128-fold.

To determine whether exposure to one antibiotic resulted in a change in susceptibility to the other antibiotics, the 15-times passaged cultures were used at about 10^7 cells/ml to determine the MIC and MBC of the other agents. Data in Table 5 show some indication of cross-resistance between cephamicin C and the cephalosporins, in that the cephamicin C-exposed cultures had cephalosporin MIC values in this test approximately eightfold those of the parent culture. The streptomycin-resistant culture was susceptible to cephamicin C and to both cephalosporins. The cephalothin-exposed culture was susceptible to all of the antibiotics, but the cephaloridine-exposed culture had a 32-fold decrease in susceptibility to

TABLE 1. Agar dilution minimal inhibitory concentrations

| Test organism | MSD no. ^a | MIC ($\mu\text{g}/\text{mg}$ of agar) | | | | | |
|---|----------------------|--|----------------|------|------------------|--------------------|----------------------|
| | | Cephamycins | | | Cephalo- thin | Cephalo- ridine | Cephalo- sporin C |
| | | A | B ^b | C | | | |
| <i>Aerobacter aerogenes</i> | 3148 | 200 | >100 | 100 | 13 | 3 | 100 |
| | 3290 ^c | >400 | >100 | >800 | >100 | >100 | >100 |
| | 3309 ^c | >400 | >100 | >800 | >100 | >100 | >100 |
| <i>A. cloacae</i> | 2646 ^c | >400 | >100 | >800 | >100 | >100 | >100 |
| <i>Aerobacter-Klebsiella</i> | 3253 ^c | 400 | >100 | 25 | 13 | 6 | 100 |
| <i>Escherichia coli</i> | 2017 | 400 | >100 | 25 | 6 | 3 | >100 |
| | 3296 ^c | >400 | >100 | 50 | 25 | 3 | >100 |
| | 3349 ^c | >400 | >100 | 13 | 50 | 6 | >100 |
| <i>Klebsiella pneumoniae</i> | 3083 ^c | 400 | >100 | 6 | 13 | 13 | 50 |
| | C-17 | 400 | >100 | 25 | 25 | 6 | 100 |
| <i>Paracolonobacterum arizonae</i> | 3271 | 400 | >100 | 13 | 3 | 3 | 50 |
| <i>Pasteurella multocida</i> | 1590 | 3 | | 6 | 0.2 | 0.4 | 3 |
| <i>Proteus mirabilis</i> | 3255 ^c | 13 | >100 | 6 | 6 | 6 | 6 |
| | 3306 ^c | 0.8 | >100 | 0.4 | 0.4 | 0.4 | 0.4 |
| | 3343 ^c | 6.0 | >100 | 6 | 13 | 100 | 13 |
| <i>P. morganii</i> | 3202 | >400 | >100 | 13 | >100 | >100 | >100 |
| | 3376 ^c | >400 | >100 | 13 | >100 | 100 | >100 |
| <i>P. vulgaris</i> | 1810 | 13 | 25 | 3 | 50 | | |
| | 169 | 25 | 100 | 13 | 6 | | |
| <i>Proteus sp.</i> | 191 | >100 | >100 | 50 | >100 | | |
| | 235 | >100 | >100 | 50 | >100 | | |
| | 343 | >100 | >100 | 50 | >100 | | |
| | 359 | >100 | >100 | 25 | 25 | | |
| <i>Providencia</i> | 50 | >100 | >100 | 6 | >100 | | |
| | 946 | >100 | >100 | 6 | >100 | | |
| <i>Pseudomonas aeruginosa</i> | 3210 | >400 | >100 | >800 | >100 | >100 | >100 |
| | 3254 ^c | >400 | | >800 | >100 | >100 | >100 |
| | 3301 | >400 | >100 | >800 | >100 | >100 | >100 |
| <i>Salmonella pullorum</i> | 3198 | 100 | >100 | 13 | 0.8 | 0.4 | 13 |
| <i>S. schottmuelleri</i> | 3010 | 400 | >100 | 25 | 13 | 1.6 | 50 |
| <i>Serratia</i> | 3347 ^c | >400 | >100 | >800 | >100 | >100 | >100 |
| <i>Shigella</i> | 3304 | 400 | >100 | 13 | 13 | 1.6 | >100 |
| <i>Diplococcus pneumoniae</i> | 3377 | 100 | 25 | 200 | 0.2 | 0.5 | 50 |
| <i>Erysipelothrix rhusio-</i> <i>pathiae</i> | 3162 | 100 | >100 | 25 | 1.6 | 0.05 | >100 |
| <i>Staphylococcus aureus</i> | 2949 | 200 | >100 | 800 | 0.2 | 0.05 | 100 |
| | 3051 ^c | 400 | >100 | 800 | 0.8 | 0.8 | >100 |
| | 3089 ^c | 400 | >100 | 800 | 0.8 | 0.8 | >100 |
| | 3106 ^c | 400 | >100 | 800 | 0.8 | 1.6 | >100 |
| | 3147 ^c | 400 | >100 | 800 | 0.4 | 1.6 | >101 |
| | 3363 ^c | 400 | >100 | 800 | 0.4 | 0.1 | >100 |
| <i>Streptococcus agalactiae</i> | 1934 | 200 | 100 | 400 | 0.9 | | 50 |
| <i>S. pyogenes</i> | 1685 | 100 | 100 | 200 | 0.9 | | 50 |
| | 3009 | 100 | >100 | 200 | 0.9 | | 50 |

^a Merck Sharp & Dohme stock culture collection number.

^b Data for cephamycin B and all data for strains of *P. vulgaris* and *Providencia* were obtained in tests not run simultaneously with the one providing the remaining data.

^c Known to produce penicillinase, cephalosporinase, or to have multiple antibiotic resistance.

cephalothin and an 8-fold decrease in susceptibility to cephamycin C.

DISCUSSION

Cephamycins A, B, and C are naturally produced antibiotic agents chemically related to the

cephalosporins. The most active of these is cephamycin C. Although this antibiotic is not highly active against gram-positive bacteria, its activity against many gram-negative organisms is greater than that of the naturally produced cephalosporin C. The ability of cephamycin C to

resist degradation by certain cephalosporinases may account for its inhibition of *P. morganii* (submitted for publication), which is known to produce such an enzyme. Against the cephalos-

porin-susceptible gram-negative organisms, cephamycin C was essentially as active as the semisynthetic compounds cephalothin and cephaloridine.

TABLE 2. *In vitro* activity of cephamycin C against some cephalosporin-resistant clinically isolated cultures

| Test organism | End point ^a (μg/ml) | | | | | | | |
|------------------------------|--------------------------------|--------|-------------|--------|---------------|--------|--------------|--------|
| | Cephamycin C | | Cephalothin | | Cephaloridine | | Streptomycin | |
| | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC |
| <i>Proteus</i> sp. 3348 | 8 | 47 | 63 | 63 | 750 | 1,000 | 66 | 66 |
| <i>P. mirabilis</i> 3343 | 16 | 63 | 156 | 190 | 1,000 | 1,000 | 16 | 16 |
| <i>P. mirabilis</i> 3347 | 47 | 63 | 63 | 63 | 1,000 | 1,000 | 16 | 31 |
| <i>P. morganii</i> 3376 | 94 | >1,000 | 4,000 | >8,000 | 2,000 | >8,000 | >1,000 | >1,000 |
| <i>P. morganii</i> 3345 | 63 | 63 | >1,000 | >1,000 | 1,000 | 1,000 | 16 | 16 |
| <i>Escherichia coli</i> 3349 | 16 | 16 | 110 | 140 | 140 | 297 | 14 | 14 |

^a Minimal inhibitory concentrations (MIC) determined in brain-heart infusion broth containing 10⁴ cells/ml. Minimal bactericidal concentrations (MBC) determined by subculture into broth. Figures given are averages of two tubes except that readings from four tubes were averaged for the *E. coli* data.

^b Cephalosporin-susceptible.

TABLE 3. *In vitro* inoculum effect

| Drug | <i>Proteus mirabilis</i> 3347 inoculum | | | | | | Fold increase | |
|---------------|--|--------|---------------------------|-------|---------------------------|-----|---------------|------|
| | 4 × 10 ⁷ cells | | 4 × 10 ⁶ cells | | 4 × 10 ⁸ cells | | MIC | MBC |
| | MIC | MBC | MIC | MBC | MIC | MBC | | |
| Cephamycin C | 63 ^a | 500 | 23 | 63 | 6 | 31 | 10 | 16 |
| Cephalothin | 8,000 | >8,000 | 94 | 312 | 31 | 31 | 260 | >260 |
| Cephaloridine | >8,000 | >8,000 | 2,000 | 3,000 | 38 | 38 | 205 | >205 |

^a Micrograms per milliliter in brain-heart infusion broth.

TABLE 4. Transfer of *Escherichia coli* 2017 through antibiotic-containing broth^a

| Exposure no. | Cephamycin C | | Cephalothin | | Cephaloridine | | Streptomycin | |
|--------------|--------------|--------------------|-------------|------------------|---------------|--------------------|---------------------|---------------------|
| | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC |
| 1 | 31 | 375 | 125 | 500 | 16 | 94 | 31 | 31 |
| 2 | 31 | 94 ^b | 31 | 141 ^b | 16 | 188 ^b | 47 | 47 |
| 3 | 31 | 63 | 63 | 375 | 13 | 31 | 63 | 63 |
| 4 | 63 | 63 | 94 | 250 | 16 | 375 | 188 | 188 |
| 5 | 63 | 63 | 125 | 500 | 47 | 281 | 125 | 125 |
| 6 | 63 | 94 | 94 | 500 | 63 | 1,000 ^b | 250 | 625 ^b |
| 7 | 63 | 156 ^b | 125 | 375 | 94 | 94 | 250 | 250 |
| 8 | 63 | 63 | 125 | 625 | 125 | 563 ^b | 250 | 375 |
| 9 | 94 | 94 | 125 | 1,000 | 375 | >1,000 | >2,000 ^b | >2,000 ^b |
| 10 | 94 | 125 | 125 | 1,000 | 500 | 750 | >8,000 | >8,000 |
| 11 | 125 | 313 ^b | 188 | 1,000 | 1,000 | 1,000 | >32,000 | >32,000 |
| 12 | 125 | 125 | 94 | 1,000 | 1,000 | 1,000 | >32,000 | >32,000 |
| 13 | 125 | 313 ^b | 125 | 750 | 2,000 | 2,000 | >32,000 | >32,000 |
| 14 | 125 | 4,000 ^b | 125 | 1,000 | 2,000 | 8,000 | >32,000 | >32,000 |
| 15 | 125 | 125 | 188 | 1,000 | 2,000 | >8,000 | >32,000 | >32,000 |

^a Values are average of two tubes and are expressed in micrograms per milliliter of brain-heart broth. In all cases, inocula contained 10⁶ to 10⁷ cells/ml. MIC read after 48 hr and MBC read after 72 hr incubation at 37 C.

^b Skipped tubes.

TABLE 5. Cross-resistance of drug-exposed cultures of *Escherichia coli* 2017^a

| Exposure of culture | Cephamycin C | | Streptomycin | | Cephalothin | | Cephaloridine | |
|---|--------------|-------|------------------|------------------|-------------|--------|---------------|--------|
| | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC |
| Unexposed | 31 | 188 | 63 | 63 | 63 | 500 | 16 | 250 |
| Exposed 15 times to cephamycin C | 250 | 250 | 156 ^b | 156 ^b | 500 | >2,000 | 125 | 125 |
| Exposed 15 times to streptomycin | 16 | 78 | >32,000 | >32,000 | 31 | 94 | >3.9 | 23 |
| Exposed 15 times to cephalothin | 31 | 1,000 | 63 | 63 | 94 | 500 | 13 | 500 |
| Exposed 15 times to cephaloridine | 250 | 375 | 63 | 63 | 2,000 | >2,000 | 2,000 | >8,000 |

^a Values are averages of two tubes and are expressed in micrograms per milliliter of brain-heart broth. MIC read about 48 hr, and MBC read about 72 hr; incubation at 37 C. In all cases, inocula contained 10⁷ cells/ml.

^b Skipped tube.

ACKNOWLEDGMENT

We are pleased to recognize the excellent assistance of Donald Glover.

LITERATURE CITED

1. Miller, A. K., E. Celozzi, Y. Kong, B. A. Pelak, H. Kropp, E. O. Stapley, and D. Hendlin. 1972. Cephamycins, a new family of β -lactam antibiotics. IV. In vivo studies. *Antimicrob. Ag. Chemother.* 2:287-290.
2. Stapley, E. O., M. Jackson, S. Hernandez, S. B. Zimmerman, S. A. Currie, S. Mochales, J. M. Mata, H. B. Woodruff, and D. Hendlin. 1972. Cephamycins, a new family of β -lactam antibiotics. I. Production by Actinomycetes, including *Streptomyces lactandurams*, sp n.. *Antimicrob. Ag. Chemother.* 2:122-131.
3. Steers, E., E. L. Foltz, and B. S. Graves. 1959. An inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics. *Antibiot. Chemother.* 9:307-311.